Higher levels of matrix metalloproteinase-3 in patients with RA reflect disease activity and structural damage

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73583550" target="_blank" >RIV/61989592:15110/17:73583550 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/17:N0000034

Výsledek na webu

<a href="http://dx.doi.org/10.5507/bp.2017.015" target="_blank" >http://dx.doi.org/10.5507/bp.2017.015</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2017.015" target="_blank" >10.5507/bp.2017.015</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Higher levels of matrix metalloproteinase-3 in patients with RA reflect disease activity and structural damage

Popis výsledku v původním jazyce

Aims. To evaluate the serum levels of matrix metalloproteinase-3 (MMP-3) as a potential marker of disease aktivity and joint damage in 92 patients with rheumatoid arthritis (RA), compared to 24 osteoarthritis (OA) patients and 26 healthy controls. Methods. The concentrations of MMP-3 were measured by ELISA using the commercial kit AESKULISA DF MMP-3 (AESKU.Diagnostics, Germany) and compared with other laboratory parameters routinely used to assess the dinase status, clinical score (DAS28) and radiographic stage in the group of RA patients. Results. The mean serum concentrations of MMP-3 were 199.1 ± 160 ng/mL in RA patients, 113.9 ± 96.9 ng/mL in OA patients and 48.3 ± 19.2 in healthy controls. The differences were highly significant: RA patients and healthy controls (P&lt;0.0001), RA and OA patients (P=0.008) as well as between OA patients and controls (P=0.009). MMP-3 concentrations were further compared with other laboratory parameters and clinical and structural damage data. There were correlations between MMP-3 and CRP (r=0.304, P&lt;0.01), DAS28 (r=0.301, P&lt;0.05), levels of anti-cyclic citrullinated peptide antibodies (r=0.241, P&lt;0.05), erythrocyte sedimentation rate (r=0.200, P=0.059) and radiographic disease stage (r=0.197, P=0.063). Conclusion. These results demonstrated that measurement of MMP-3 could become a marker of disease activity in RA patients.

Název v anglickém jazyce

Higher levels of matrix metalloproteinase-3 in patients with RA reflect disease activity and structural damage

Popis výsledku anglicky

Aims. To evaluate the serum levels of matrix metalloproteinase-3 (MMP-3) as a potential marker of disease aktivity and joint damage in 92 patients with rheumatoid arthritis (RA), compared to 24 osteoarthritis (OA) patients and 26 healthy controls. Methods. The concentrations of MMP-3 were measured by ELISA using the commercial kit AESKULISA DF MMP-3 (AESKU.Diagnostics, Germany) and compared with other laboratory parameters routinely used to assess the dinase status, clinical score (DAS28) and radiographic stage in the group of RA patients. Results. The mean serum concentrations of MMP-3 were 199.1 ± 160 ng/mL in RA patients, 113.9 ± 96.9 ng/mL in OA patients and 48.3 ± 19.2 in healthy controls. The differences were highly significant: RA patients and healthy controls (P&lt;0.0001), RA and OA patients (P=0.008) as well as between OA patients and controls (P=0.009). MMP-3 concentrations were further compared with other laboratory parameters and clinical and structural damage data. There were correlations between MMP-3 and CRP (r=0.304, P&lt;0.01), DAS28 (r=0.301, P&lt;0.05), levels of anti-cyclic citrullinated peptide antibodies (r=0.241, P&lt;0.05), erythrocyte sedimentation rate (r=0.200, P=0.059) and radiographic disease stage (r=0.197, P=0.063). Conclusion. These results demonstrated that measurement of MMP-3 could become a marker of disease activity in RA patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30226 - Rheumatology

Projekt

<a href="/cs/project/NV15-28659A" target="_blank" >NV15-28659A: Prognostické faktory rozvoje orgánového a tkáňového postižení u vybraných systémových chorob pojiva</a><br>

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers-Olomouc

ISSN

1213-8118

e-ISSN

—

Svazek periodika

161

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

296-302

Kód UT WoS článku

000418004800009

EID výsledku v databázi Scopus

—